SAN FRANCISCO, CA, Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, announced the closing of a $37 million oversubscribed financing led by Structure Fund.
Continue Reading
Sign up for FREE to read the full article and access 131K+ alternative investment headlines.